Fluoride: Page 55

Head/neck cancer drug shows promise in clinical trials

By DrBicuspid.com staff writers

CEL-SCI has begun a phase III clinical trial for Multikine, its flagship immunotherapy drug for head and neck cancer. The goal is to establish Multikine as a first-line standard of care therapy in treating newly diagnosed head and neck cancer patients.

January 5, 2011

Private equity firm acquires OraPharma

By Kathy Kincade

Water Street Healthcare Partners, a strategic private equity firm, has acquired OraPharma from Johnson & Johnson and plans to build it into a leading specialty pharmaceutical company focused on dental and oral healthcare.

January 4, 2011

Zometa aids patients with head and neck cancer

By DrBicuspid.com staff writers

The bisphosphonate Zometa appears to reduce bone loss and decrease tumor size in patients with head and neck cancer, according to a study in Cancer Research.

December 12, 2010

4th Fosamax ONJ lawsuit going to trial

By DrBicuspid.com staff writers

Another lawsuit against Merck alleging that its Fosamax bisphosphonate drug causes osteonecrosis of the jaw (ONJ) will go to court beginning May 9, 2011, according to a story on aboutlawsuits.com.

December 9, 2010

Prolonged preop antibiotic regime enhances BRONJ outcomes

By DrBicuspid.com staff writers

Combining surgery with long-term preoperative antibiotic therapy yields the best treatment outcomes in patients suffering from bisphosphonate-related osteonecrosis of the jaw (BRONJ), according to a new study in the Journal of Oral and Maxillofacial Surgery.

December 2, 2010

Novalar donates OraVerse to NCOHF dentists

By DrBicuspid.com staff writers

Novalar Pharmaceuticals has donated more than $100,000 worth of its OraVerse anesthetic-reversal product to the National Children's Oral Health Foundation (NCOHF) affiliate network.

November 29, 2010

Novartis loses 3rd ONJ/bisphosphonate trial

By DrBicuspid.com staff writers

The family of a North Carolina woman has been awarded nearly $13 million in a lawsuit over bisphosphonate-induced osteonecrosis of the jaw (ONJ), according to an article on Aboutlawsuits.com.

November 28, 2010

Start-up raises $10M for sleep apnea drug

By DrBicuspid.com staff writers

A start-up company in Philadelphia has raised $10 million to develop pharmaceuticals to treat sleep apnea and other breathing control conditions.

November 22, 2010

Merck wins 3rd Fosamax/ONJ lawsuit

By DrBicuspid.com staff writers

Merck has come out on top in the latest Fosamax/osteonecrosis of the jaw (ONJ) lawsuit. On November 19, a federal court jury in New York rejected the claims of a Florida woman who blamed her dental and jaw-related problems on her use of the bisphosphonate Fosamax, which is prescribed for osteoporosis.

November 21, 2010

Xanodyne to withdraw propoxyphene from the U.S. market

By DrBicuspid.com staff writers

Xanodyne Pharmaceuticals, which makes Darvon and Darvocet -- the brand version of the prescription pain medication propoxyphene -- has agreed to withdraw the medication from the U.S. market after researchers found it can cause adverse heart conditions.

November 18, 2010

3rd Fosamax/ONJ trial begins in NY

By DrBicuspid.com staff writers

Another trial involving Fosamax and its alleged role in osteonecrosis of the jaw (ONJ) is now under way in New York, according to an article in the New York Times.

November 10, 2010

Study: Patients on bisphosphonates at low risk for ONJ

By Rabia Mughal

Occurrences of bisphosphonate-related osteonecrosis of the jaw (ONJ) may be rare in patients receiving once-a-year infusions of 5 mg of zoledronic acid, a new study in the Journal of the American Dental Association has found.

November 8, 2010

Previous Page

Page 55 of 62

Next Page